U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™
Pfizer
DECEMBER 20, 2022
Nirmatrelvir is designed to inhibit viral replication at a stage known as proteolysis, which occurs before viral RNA replication. One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. Investor Relations. +1
69 
Let's personalize your content